Regeneron Pharmaceuticals (REGN) and Absci (ABSI): Two Digital Biology Investment Briefs

Why This Could Work
Dupixent profit growth and the end of a historical development-cost reimbursement can outweigh erosion in the retinal franchise over the next two years. The investment can work without assigning a premium to AI or assuming a blockbuster from an unproven program.

Regeneron’s TriNetX agreement provides licensed access to de-identified health records covering approximately 300 million people, with the opportunity to connect a subset to genomic and proteomic data. That creates a relevant discovery asset; it is neither ownership of 300 million genomes nor a new data-revenue forecast. ⁶

What Supports the Entry

Sources ^{3 4}

The Earnings Bridge H1 collaboration revenue was reduced by $530M of historical Sanofi development reimbursements. That obligation is fully repaid, with no further reduction from Q3. Annualized H1 adjusted EPS of $47.44 plus a simplified $8.27 per-share after-tax normalization gives roughly $55.71.

Derived illustration: $530M × 2 × (1 − 15% assumed tax) ÷ 108.9M H1 adjusted diluted shares = $8.27. This holds other economics constant; it is not company EPS guidance. It does not eliminate ongoing R&D spending. Sanofi also disclosed favorable gross-to-net adjustments in Q2 Dupixent sales, so extrapolating that quarter alone would overstate confidence. ^{4 7}

What the Market May Be Missing

Our proposed difference in view is that retinal-franchise weakness and disappointment in the pipeline may overshadow the value of retained collaboration profits. This is a falsifiable investment interpretation, not a claim that analyst models omit the reimbursement change; a current consensus model series was not available.

The contrary view is substantial: total U.S. Eylea/HD sales fell 12% in Q2 even while HD grew. Fianlimab’s Phase 3 melanoma study missed its primary endpoint. Dupixent’s U.S. composition-of-matter protection expires in March 2031, although other patents extend later. Patent expiry is not an automatic biosimilar launch date, but replacement earnings must be demonstrated. ^{3 5}

Illustrative 24-Month Valuation

Analyst assumptions, not company guidance or probability-weighted targets. Multiples explicitly reflect varying earnings duration; they are not sourced peer averages. Returns exclude dividends, taxes and costs. Central-case annualized price return is about 14.7%. At only 15× the same $55 EPS, value is $825, just 10% above the entry. The central payoff therefore needs some multiple support. Outcomes can fall outside these cases.

How We Would Approach It: roughly $750 is a reasonable staged-entry candidate under these assumptions. About $760 is the maximum entry for 30% price upside to the $990 central case; this is an arithmetic hurdle, not a technical support level. A $650–700 quote with an intact thesis offers a more attractive margin. Above $900, the same model leaves too little reward to initiate aggressively.

What Would Strengthen the Case: two quarters of improving retained collaboration profits, underlying prescription growth and cash conversion, while total retinal-franchise declines stabilize. What Would Make Us Walk Away: Dupixent demand deceleration alongside persistent retinal erosion, materially worse patent durability, or a large acquisition that destroys the balance-sheet advantage. A fall in the price alone is not a reason to add.

Why This Could Work
ABS-201 could become a differentiated treatment for pattern hair loss if prolactin-receptor blockade produces meaningful, durable regrowth with infrequent injections. Positive results could also validate part of Absci’s antibody-design approach. Today, the stock is principally a clinical bet on this molecule.

What Has Been Demonstrated June’s human update covered 32 participants and pooled, blinded safety/pharmacokinetic observations. Estimated half-life was at least 65 days. No randomized hair-regrowth efficacy was established by that announcement. Exposure and tolerability support continued testing; they do not establish benefit. ¹⁰

The multiple-dose study is designed to include 147 participants with androgenetic alopecia across three cohorts, with placebo controls. Hair-count and related efficacy measures are secondary endpoints; safety and tolerability are primary. The key questions are placebo-adjusted effect, dose response, durability, tolerability and a commercially practical dose—not selected photographs. ¹¹

Can the Company Fund the Next Step?

At $9.49 and 171.614M shares outstanding on July 31, equity value is approximately $1.63B. Using June cash/securities of $201.14M and $0.15M debt gives approximately $1.43B enterprise value. This is a dated balance-sheet bridge, not today’s fully diluted capitalization.

H1 operating cash use was $53.87M. June’s reported options and unvested RSUs total approximately 27.6M, before future grants or financing. More shares are likely in a successful development path. Cash should not be treated as a liquidation floor. ⁸

Management guides funding into H2 2028, sufficient to pursue the next key experiments, not commercialization. Lilly participated with $40M in June’s $100M equity offering. That investment provides strategic corroboration; it is not regulatory validation or a guaranteed drug partnership. ⁹

How Much Success Is Already Required?

Work backward from the desired return to the required business scale. Assume 220M eventual shares—28% above the current reported base—and an illustrative 4× commercial annual sales equity valuation, with zero net cash/debt at that future point.

Analyst commercial-success assumptions, not fair values today or targets for the next readout. The share count and sales multiple are sensitivities rather than forecasts. Clinical development, launch spending and time value must be funded. More dilution or a lower multiple raises the required sales. At 2× sales, the tenfold case needs $10.44B annual revenue. Durable benefit can also reduce repeat-treatment revenue.

A hypothetical $1–3 failure-price stress means 68–89% downside; a near-total loss is possible. A middling trial outcome may leave a cash-consuming company without a clear development advantage. Good data would improve the thesis, but approval, safety at scale, reimbursement or cash-pay demand and competition would still matter.

Why “asymmetric” is conditional: a hypothetical $25 success outcome versus $2 failure requires a 32.6% success probability just to break even from $9.49 before time discounting. If success pays $19, that threshold is 44.1%. Public evidence does not establish either probability. Large possible upside alone cannot prove a favorable bet.

Why Absci Takes the Moonshot Slot

Recursion offers more programs and broader potential validation. Its H1 operating cash use of $187M was roughly 3.5× Absci’s, making the capital burden heavier. Absci supplies a more focused test with lower current cash consumption; that concentration also makes failure more damaging. ^{15 8}

AbCellera has stronger efficacy evidence today: its controlled Phase 2 hot-flash study showed a 5.3-per-day placebo-adjusted improvement at week four. Absci is selected for the payoff potential of an earlier, more concentrated bet, not because its science is more de-risked. This comparison is judgment; a complete asset-by-asset valuation could change the ranking. ¹⁶